ABSTRACT
BACKGROUND: Inflammatory Bowel Disease (IBD) affects reproductive-aged women. Active disease can lead to decreased fertility. Although the vast majority of international guidelines recommend for the continuation of anti-TNF-α during pregnancy, recent studies have raised concerns about the safety of anti-tumor necrosis factor-α (TNF-α) therapy during pregnancy, both for patients and for physicians. METHODS: Studies that evaluate the safety of anti-TNF-α therapy in pregnant women with IBD were identified using bibliographical searches. An updated meta-analysis was performed for pregnancy outcomes, such as live birth, abortion, still birth, preterm birth, low birth weight, congenital abnormalities, and neonatal infection. Odds ratio (OR) with 95% confidence interval (CI) are reported. Data on disease activity, timing of anti-TNF-α therapy were collected for further analysis. RESULTS: Overall, 11 studies were screened from on-line databases and international meeting abstracts. An increased risk of abortion (OR, 1.33; 95% CI, 1.02-1.74; P = 0.04) and preterm birth (OR, 1.16; 95% CI, 1.05-1.28; P = 0.004), and a decreased risk of live birth (OR, 0.83; 95% CI, 0.74-0.94; P = 0.002]) were found in the anti-TNF-α therapy group compared with the control group (no use of anti-TNF-α therapy). The subgroup analyses based on the disease activity showed there is no significant association between the use of anti-TNF-α therapy during pregnancy on adverse pregnancy outcomes of abortion, preterm birth, and live birth. The rates of still birth, low birth weight, and congenital abnormalities in the anti-TNF-α therapy group were not significantly different from those in the control group. CONCLUSIONS: Anti-TNF-α therapy does not increase the risks of still birth, low birth weight, and congenital abnormalities; however it may be assicated with increased risks of abortion and preterm birth, which are accompanied by a lower rate of live birth. Although these findings may be confounding by potential disease activity, they offer some opposite viewpoints with biologic agent use. Therefore, more studies are required to further confirm the safety of anti-TNF-α therapy in pregnancy with IBD.
Subject(s)
Adalimumab , Inflammatory Bowel Diseases , Pregnancy Complications , Pregnancy Outcome , Premature Birth , Tumor Necrosis Factor-alpha , Humans , Pregnancy , Female , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Inflammatory Bowel Diseases/drug therapy , Pregnancy Complications/drug therapy , Premature Birth/epidemiology , Pregnancy Outcome/epidemiology , Adalimumab/therapeutic use , Adalimumab/adverse effects , Infliximab/therapeutic use , Infliximab/adverse effects , Abortion, Spontaneous/epidemiology , Abortion, Spontaneous/chemically induced , Infant, Newborn , Infant, Low Birth WeightABSTRACT
BACKGROUND: The optimal dosage of new generation proton pump inhibitors (PPIs) in increasing cure rate of Helicobacter pylori (H. pylori) infection remains unclear. This network meta-analysis aimed to comprehensively evaluate the comparative efficacy and safety of different dosages of esomeprazole and rabeprazole in treating H. pylori infection. MATERIALS AND METHODS: We searched PubMed, Cochrane Central Registry for Controlled Trials (CENTRAL), and EMBASE for randomized controlled trials (RCTs) involving esomeprazole and rabeprazole with different dosages from their inception through 31 March, 2022. After data extraction and risk of bias assessment, network meta-analyses were conducted using STATA 14.0. We calculated the surface under the cumulative ranking (SUCRA) to rank all regimens. RESULTS: Thirteen studies including 14 reports were included. Six dosages including rabeprazole 10 mg (R10bid), 20 mg (R20bid), and 40 mg (R40bid) twice daily and esomeprazole 20 mg (E20bid) and 40 mg (E40bid) twice daily as well as 40 mg once daily (E40qd) were identified. Network meta-analysis suggested that R40bid ranked highest in the cure rate (83.8%), followed by E40bid (82.6%), E20bid (54.5%), R20bid (34.2%), R10bid (22.8%), and E40qd (22.0%); however, E40qd ranked highest in adverse events (91.1%), followed by R20bid (57.8), R10bid (57.6%), E20bid (38.9%), E40bid (34.2%), and R40bid (20.4%). Sensitivity analyses confirmed the robustness of these results. CONCLUSIONS: Based on the available evidence, R40bid and E40bid might be the optimum dosage to increase the cure rate; however, E40qd was superior for adverse events. Nevertheless, future studies should validate the results from this network meta-analysis.
Subject(s)
Helicobacter Infections , Helicobacter pylori , Humans , Esomeprazole/therapeutic use , Rabeprazole/therapeutic use , Helicobacter Infections/drug therapy , Network Meta-Analysis , Proton Pump Inhibitors/therapeutic use , Drug Therapy, Combination , Treatment Outcome , Anti-Bacterial Agents/therapeutic useABSTRACT
The maximum entropy (MaxEnt) model for predicting the potential suitable habitat of species has been commonly employed in many ecological and biological applications by using presence-only occurrence records along with associated environmental factors. Parnassiawightiana, a perennial herb, is a cold-adapted plant distributed across three diversity hotspots in China, including the Hengduan Range, Central China and the Lingnan region. The MaxEnt model was used to simulate the historic, current and future distribution trends of P.wightiana, as well as to analyse its distribution pattern in each historical period and explore the causes of species distribution changes. The results of our analysis indicated that annual precipitation, annual temperature range and mean temperature of the warmest quarter were the key bioclimatic variables affecting the distribution of P.wightiana. Most temperate species retracted into smaller refugial areas during glacial periods and experienced range expansion during interglacial periods. Possible refugia of the species were inferred to be located in the Hengduan Range and Qinling Regions.
ABSTRACT
OBJECTIVES: To evaluate the safety and efficacy of high-dose amoxicillin-proton pump inhibitor dual therapy, and to provide a new eradication regimen as a first-line option for patients with H. pylori infection. METHODS: A total of 971 H. pylori positive patients who received initial treatment were recruited from March to August 2020, and randomly divided into treatment group and control group. The treatment group received of 20 mg esomeprazole four times daily and 750 mg amoxicillin four times daily for 14 days. Control group received of 220 mg bismuth potassium citrate twice daily, 20 mg esomeprazole twice daily, 1000 mg amoxicillin twice daily and 250 mg clarithromycin capsule twice daily for 14 days. Four weeks after the end of treatment, the urea breath test was reviewed to detect whether H. pylori was eradicated. RESULTS: There were no statistical differences in age, gender, the total clinical symptom scores before and after initial treatment, the compliance, and the degree of remission of symptoms before and after initial treatment between the two groups. The eradication rates of H. pylori between dual therapy and quadruple therapy were 88.31% and 85.26% (p=.158) by intention-to-treat (ITT) analysis, 88.66% and 85.44% (p=.186) by modified intention-to-treat (mITT) analysis, and 91.63% and 90.60% (p=.116) by PP analysis, respectively. Adverse events in dual therapy group were significantly lower than quadruple therapy group (13.3% vs. 28.2% (p<.01)). CONCLUSIONS: For the initial treatment of H. pylori infection, the high-dose dual therapy regimen has the same efficacy as the bismuth-containing quadruple therapy regimen, good compliance, less adverse reactions and high safety, so it can be recommended as the empirical first-line treatment regimen for the eradication of H. pylori (KY2019173).
Subject(s)
Helicobacter Infections , Helicobacter pylori , Amoxicillin/adverse effects , Anti-Bacterial Agents , Drug Therapy, Combination , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Humans , Prospective Studies , Proton Pump Inhibitors/adverse effects , Treatment OutcomeABSTRACT
Background: Long noncoding RNAs (lncRNAs) are associated with the survival of cancer patients. We constructed an immune-related lncRNA (irlncRNA) pair signature for stomach adenocarcinoma (STAD).Research design and methods: irlncRNAs were identified via coexpression analysis with immune-related genes. Differentially expressed irlncRNAs (DEirlncRNAs) were paired. Least absolute shrinkage and selection operator (LASSO) and multivariate Cox proportional hazards regression methods were used to construct the signature. We calculated the area under the receiver operating characteristic (ROC) curve and determined the best cutoff value according to the Akaike information criterion (AIC). Patients were divided into high - and low-risk groups, and differences in immune cell infiltration, tumor mutation burden (TMB) and drug treatment effects between the groups were explored according to the risk score.Results: An 8-irlncRNA-pair signature was constructed and proven to be a strong prognosis predictor in STAD patients through external verification. Moreover, the risk score was identified as an independent prognostic factor. There were significant differences in immune cell infiltration and the response to several drug treatments between patients with high and low risk scores, and the risk score was negatively correlated with TMB.Conclusions: The signature consisting of 8 irlncRNA pairs showed good prognostic predictive value.
Subject(s)
Adenocarcinoma , RNA, Long Noncoding , Stomach Neoplasms , Adenocarcinoma/genetics , Humans , Prognosis , RNA, Long Noncoding/genetics , Stomach Neoplasms/geneticsABSTRACT
Based on investigation of populations of Parnassiaguilinensis and P.xinganensis, examination of herbarium specimens (including types), as well as consultation of protologues and distributions, P.guilinensis is hereby reduced to a synonym of P.xinganensis. P.xinganensis is endemic to northeastern Guangxi Province of China and characterized by having elliptic to ovate leaves and staminodes 3-5-branched with globose glands. Field photographs and an updated morphological description of P.xinganensis are provided.